An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2022 Mar 31

PMID 35357604

Authors

Jeffrey Triska

Juan Tamargo

Biykem Bozkurt

Uri Elkayam

Addison Taylor

Yochai Birnbaum

Affiliations

Soon will be listed here.

Abstract

Purpose: The 2021 European Society of Cardiology guidelines on acute and chronic heart failure (HF) recommend that non-dihydropyridine calcium channel blockers (NDCC) should be avoided in patients with HF with reduced ejection fraction. It also emphasizes that beta-blockers only be initiated in clinically stable, euvolemic patients. Despite these recommendations, NDCC and beta-blockers are often still employed in patients with AF with rapid ventricular response and acute decompensated HF. The relative safety and efficacy of these therapies in this setting is unclear.

Methods: To address the question of the safety and efficacy of NDCC and beta-blockers for acute rate control in decompensated HF, we provide a perspective on the literature of NDCC and beta-blockers in chronic HF with reduced and preserved ejection fraction and AF, including trials on the management of AF with rapid ventricular response with and without HF.

Results: Robust data demonstrates mortality benefits when beta-blockers are used in patients with chronic HF with reduced ejection fraction. The data that inform the contraindication of NDCC in HF with reduced ejection fraction are outdated and were not primarily designed to address the efficacy and safety of rate control of AF in patients with HF. Several studies indicate that for acute rate control, NDCC and beta-blockers are both efficacious therapies, especially in the setting of tachycardia-induced cardiomyopathy.

Conclusion: Future studies are needed to assess the safety and efficacy of beta-blockers and NDCC in both acute and chronic AF with HF with reduced and preserved ejection fraction.

Citing Articles

Run baby run … but not too fast! Rate control management in atrial fibrillation: a claim for personalization.

Diemberger I, Boriani G Europace. 2023; 25(5).

PMID: 37083891 PMC: 10228601. DOI: 10.1093/europace/euad117.

Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study.

Diemberger I, Spadotto A, Massaro G, Amadori M, Damaschin L, Martignani C Biology (Basel). 2023; 12(1).

PMID: 36671715 PMC: 9855170. DOI: 10.3390/biology12010022.

References

Friedman H, Goldberg S, Bonema J, Cragg D, Hauser A . Acute complications associated with new-onset atrial fibrillation. Am J Cardiol. 1991; 67(5):437-9. DOI: 10.1016/0002-9149(91)90059-t. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21):e1-76. DOI: 10.1016/j.jacc.2014.03.022. View

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. View

Khasnis A, Jongnarangsin K, Abela G, Veerareddy S, Reddy V, Thakur R . Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol. 2005; 28(7):710-21. DOI: 10.1111/j.1540-8159.2005.00143.x. View

Wyse D . Therapeutic considerations in applying rate control therapy for atrial fibrillation. J Cardiovasc Pharmacol. 2008; 52(1):11-7. DOI: 10.1097/FJC.0b013e31816d5f49. View

Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J . The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009; 54(19):1747-62. DOI: 10.1016/j.jacc.2009.05.015. View

Weir M . Diltiazem: ten years of clinical experience in the treatment of hypertension. J Clin Pharmacol. 1995; 35(3):220-32. DOI: 10.1002/j.1552-4604.1995.tb04051.x. View

Chew C, Hecht H, Collett J, McALLISTER R, Singh B . Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol. 1981; 47(4):917-22. DOI: 10.1016/0002-9149(81)90194-6. View

10.

Gheorghiade M, Zannad F, Sopko G, Klein L, Pina I, Konstam M . Acute heart failure syndromes: current state and framework for future research. Circulation. 2005; 112(25):3958-68. DOI: 10.1161/CIRCULATIONAHA.105.590091. View

11.

Fujino T, Yamashita T, Suzuki S, Sugiyma H, Sagara K, Sawada H . Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J. 2007; 71(6):936-40. DOI: 10.1253/circj.71.936. View

12.

Hansen J . Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction. J Cardiovasc Pharmacol. 1991; 18 Suppl 6:S20-5. View

13.

Chen Z, Pan H, Chen Y, Peto R, Collins R, Jiang L . Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366(9497):1622-32. DOI: 10.1016/S0140-6736(05)67661-1. View

14.

Lundstrom T, Ryden L . Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol. 1990; 16(1):86-90. DOI: 10.1016/0735-1097(90)90461-w. View

15.

Ulimoen S, Enger S, Pripp A, Abdelnoor M, Arnesen H, Gjesdal K . Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2013; 35(8):517-24. DOI: 10.1093/eurheartj/eht429. View

16.

Koldenhof T, Wijtvliet P, Pluymaekers N, Rienstra M, Folkeringa R, Bronzwaer P . Rate control drugs differ in the prevention of progression of atrial fibrillation. Europace. 2021; 24(3):384-389. PMC: 8892061. DOI: 10.1093/europace/euab191. View

17.

Goldenberg I, Lewis W, Dias V, Heywood J, Pedersen W . Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol. 1994; 74(9):884-9. DOI: 10.1016/0002-9149(94)90580-0. View

18.

PHILLIPS B, Gandhi A, Sanoski C, Just V, Bauman J . Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997; 17(6):1238-45. View

19.

Demircan C, Cikriklar H, Engindeniz Z, Cebicci H, Atar N, Guler V . Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005; 22(6):411-4. PMC: 1726824. DOI: 10.1136/emj.2003.012047. View

20.

Scheuermeyer F, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B . Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med. 2013; 20(3):222-30. DOI: 10.1111/acem.12091. View